

## A SYSTEMATIC REVIEW AND META-ANALYSIS AND MENDELIAN RANDOMIZATION ANALYSIS OF SERUM PHOSPHORUS, ALBUMIN, AND CRP AS RISK FACTORS FOR DEATH IN HEMODIALYSIS PATIENTS

SISTEMATSKI PREGLED I META-ANALIZA I MENDELOVA RANDOMIZACIONA ANALIZA FOSFORA U SERUMU, ALBUMINA I CRP-A KAO FAKTORA RIZIKA SMRTI KOD PACIJENATA NA HEMODIJALIZI

Xiaofen Ma, Huan Ye\*

Blood Purification Center, Zhejiang Hospital,  
No. 12 Lingyin Road, Xihu District, Hangzhou City, Zhejiang Province, China

### Summary

**Background:** We aimed to identify hemodialysis patients' main mortality risk factors using data from relevant cross-sectional literature. We used Mendelian randomization (MR) to assess the causality of those identified risk factors using pertinent Genome-Wide Association Study (GWAS) Single Nucleotide Polymorphism (SNP) data.

**Methods:** Sixteen publications detailing hemodialysis-related mortality implicated 32 death-related risk factors. Based on heterogeneity testing, we utilized random- and stratified-effects models for meta-analysis. Sensitivity analysis and bias testing were used to evaluate data reliability. MR analysis identified type-2 diabetes (T2D), serum phosphorus, serum albumin, and age as risk factors, with haematology as the outcome. Inverse-variance weighting (IVW) analysis was used in the main study. The consistency of the IVW analysis results was evaluated simultaneously using four different methods: MR Egger regression, weighted median estimator (WME), weighted mode, and simple mode. Horizontal pleiotropy was assessed using the MR Egger regression intercept term; heterogeneity was evaluated using Cochran's Q.

**Results:** Using random- and stratified-effects models, a meta-analysis of 16 published articles revealed that the following factors were associated with a greater mortality risk in hemodialysis patients: T2D; serum phosphorus, albumin, and CRP; and the Charlson comorbidity index (CCI).

### Kratak sadržaj

**Uvod:** Naš cilj je bio da identifikujemo glavne faktore rizika smrtnosti kod pacijenata na hemodijalizi koristeći podatke iz relevantne literaturne studije preseka. Koristili smo Mendelovu randomizaciju (MR) kako bismo procenili uzročnost tih identifikovanih faktora rizika koristeći relevantne podatke iz Studije asocijacije na nivou čitavog genoma (GWAS) o polimorfizmu jednog nukleotida (SNP).

**Metode:** Šesnaest publikacija koje se bave smrtnošću povezanom sa hemodijalizom su ukazale na 32 faktora rizika povezanih sa smrću. Na osnovu testiranja heterogenosti koristili smo modele sa nasumičnim i stratifikovanim efektima za meta-analizu. Za procenu pouzdanosti podataka korišćene su analiza osetljivosti i testiranje pristrasnosti. MR analiza je identifikovala dijabetes tipa 2 (T2D), nivo fosfora u serumu, nivo albumina u serumu i starost kao faktore rizika, sa hematologijom kao ishodom. U glavnoj studiji je korišćeno inverzno slaganje varijacija (IVW). Doslednost rezultata IVW analize istovremeno je procenjena korišćenjem četiri različite metode: MR-Egger regresije, ponderisanog median estimator-a (WME), ponderisanog moda i prostog moda. Horizontalna pleiotropija je procenjena pomoću intercepta MR-Egger regresije; heterogenost je procenjena korišćenjem Cochranovog Q testa.

**Rezultati:** Koristeći modele sa nasumičnim i stratifikovanim efektima, meta-analiza 16 objavljenih članaka je otkrila da su sledeći faktori povezani sa većim rizikom od smrtnosti kod

Address for correspondence:

Huan Ye (1999.12.23-), Associate Chief Nurse, Bachelor Degree  
Research direction: Factors influencing mortality in hemodialysis patients  
e-mail: HuanYe3421@163.com  
Mailing address: Zhejiang Hospital  
No.12 Lingyin Road, Xihu District, Hangzhou City, Zhejiang Province, China

Lead author:

Xiaofen Ma (1982.12.21-), Bachelor Degree, Supervisor Nurse  
Research direction: Factors influencing mortality in hemodialysis patients  
e-mail: XiaofenMa123@163.com

The results were deemed reliable based on bias ( $P=0.1186$ ,  $I^2=99.53\%$ ) and sensitivity ( $T=0.39$ ,  $df=116$ ,  $P=0.6953$ ) analyses. IVW indicated a genetic-level positive causal relationship between T2D and haematology ( $OR=1.2572$ ,  $95\% CI=1.0375-1.5235$ ;  $P=0.0195$ ). Genetic-level serum pathology and haematology were positively correlated ( $OR=2.0269$ ,  $95\% CI=1.0614-3.8708$ ;  $P=0.0323$ ). However, age ( $OR=11.1112$ ,  $95\% CI=0.83$ ) was a factor. No discernible genetic causal relationship occurred between haematology and serum ferritin ( $OR=0.6707$ ,  $95\% CI=0.4612-0.9707$ ;  $P=0.4612$ ) or albumin ( $OR=1.2933$ ,  $95\% CI=0.8931-1.8729$ ;  $P=0.1733$ ).

**Conclusions:** Meta-analysis identified the number of dialysis sessions, serum CRP, CCI, T2D, serum phosphorus, and serum albumin as mortality risk factors in hemodialysis patients. The MR results showed positive causal relationships between T2D incidence and serum phosphorus with hemodialysis risk.

**Keywords:** renal dialysis, phosphorus, serum Albumin, C-reactive protein, mortality, Mendelian randomization analysis

## Introduction

Chronic kidney disease affects over 10% of the global population, disproportionately impacting older adults, women, and those with diabetes and hypertension. Patients receiving dialysis for over five years now comprise 33.7% of the China Research Data Service Platform population (1, 2). Despite advances in dialysis technology and patient care, mortality rates among hemodialysis patients remain high (3, 4). Studies have consistently shown that mortality rates in this population are influenced by a range of factors, including patient demographics, comorbidities, and dialysis treatment characteristics (5, 6). For example, older age, female gender, and the presence of certain comorbidities such as cardiovascular disease and diabetes have been identified as risk factors for mortality in hemodialysis patients (7, 8).

The hemodialysis dose significantly predicts patient mortality, with higher doses associated with lower mortality rates (6–8). However, the relationship between dialysis dose and mortality is complex, and the optimal dialysis dose remains a topic of debate (7, 8). Furthermore, the causes of death in hemodialysis patients are multifaceted, with infections, cardiovascular disease, and withdrawal from dialysis being common contributing factors (6–8). As a result, it is critical to investigate the risk factors linked to mortality in hemodialysis patients, create individualized plans to improve patient survival in nursing and clinical settings and establish a theoretical framework for forecasting patient mortality risk.

This cross-sectional study aimed to determine the primary risk factors linked to mortality in

pacijenata na hemodijalizi: dijabetes tipa 2 (T2D), nivo fosfora, albumina i CRP-a u serumu, kao i Charlson-ov indeks komorbiditeta (CCI). Rezultati su ocenjeni kao pouzdani na osnovu analiza pristrasnosti ( $P=0.1186$ ,  $I^2=99.53\%$ ) i osetljivosti ( $T=0.39$ ,  $df=116$ ,  $P=0.6953$ ). IVW je pokazao pozitivnu genetsku uzročnu povezanost između dijabetesa tipa 2 i hematologije ( $OR=1.2572$ ,  $95\% CI=1.0375-1.5235$ ;  $P=0.0195$ ). Genetska patologija seruma i hematologija su bili u pozitivnoj korelaciji ( $OR=2.0269$ ,  $95\% CI=1.0614-3.8708$ ;  $P=0.0323$ ). Međutim, starost ( $OR=11.1112$ ,  $95\% CI=0.83$ ) je bila značajan faktor. Nije utvrđena uočljiva genetska uzročna povezanost između hematologije i nivoa feritina u serumu ( $OR=0.6707$ ,  $95\% CI=0.4612-0.9707$ ;  $P=0.4612$ ) ili albumina ( $OR=1.2933$ ,  $95\% CI=0.8931-1.8729$ ;  $P=0.1733$ ).

**Zaključak:** Meta-analiza je identifikovala broj sesija dijalize, nivo CRP-a u serumu, Charlson-ov indeks komorbiditeta (CCI), dijabetes tipa 2 (T2D), nivo fosfora u serumu i nivo albumina u serumu kao faktore rizika od smrtnosti kod pacijenata na hemodijalizi. Rezultati Mendelove randomizacije (MR) su pokazali pozitivne uzročne veze između incidencije dijabetesa tipa 2 i nivoa fosfora u serumu sa rizikom od hemodijalize.

**Ključne reči:** bubrežna dijaliza, fosfor, serumski albumin, C-reaktivni protein, smrtnost, analiza Mendelove randomizacije

hemodialysis patients by using valuable literature as a data source. Using the GWAS database as the primary source of SNP data, MR analysis was conducted to investigate the causal relationship between mortality-related risk factors in hemodialysis patients and the genetic risk of hemodialysis.

## Materials and Methods


### Overall study design

Serum albumin, age, diabetes status, number of dialysis sessions, serum CRP concentrations, serum phosphorus concentrations, and the Charlson comorbidity index (CCI) were consistently identified as mortality risk factors through a systematic analysis of 16 included studies. This study utilized Mendelian randomization (MR) analysis to investigate the genetic causal relationship between relevant variables and hemodialysis. Please refer to *Figure 1* for details of the research process.

### Techniques for Choosing and Examining Literature for Meta-Analysis

### The inclusion, exclusion, and literature search criteria

The primary literature sources used for the literature search were the Cochrane Library, PubMed, Ovid, Web of Science, and EBSCO databases. The search was performed through December 2023. The terms »hemodialysis,« »death,« and »risk factors« were used in English. The search terms »hemodialy-



**Figure 1** Research Workflow Diagram.

sis», «hemodialysis death», and «death» or «risk factors» were combined with free words to create the search strategy. The inclusion criteria for this review included complete data from published primary literature, cross-sectional studies with a total number of cases, a reasonable study design, odds ratios (ORs) and 95% confidence intervals (CIs) for outcomes and all of the above. The exclusion criteria for this review were as follows: were written in languages other than English, were basic studies, had incomplete clinical data, lacked indicators related to deaths from hemodialysis, or full-text was not accessible.

#### *Screening of the literature, data extraction, and quality evaluation*

When there was a disagreement between the two individuals screened for inclusion and exclusion criteria, three participants were included in the study. The first author, the year the work was published, the number of patients in the control and observation groups, the interventions used in both groups, the clinical outcomes (total number of deaths or survivors), and quality assessment indicators such as blinding, randomization, and loss to follow-up in the study were among the basic literature details included in the data extraction process. The PEDro scale, a technique for assessing trial quality, was used to gauge the calibre of the included studies. Due to the inclusion criteria and participant external validity, the first question was not included in determining the

overall PEDro score. As such, there are 11 questions on the scale overall, but only 10 of them can be scored. The PEDro scale is a helpful tool for assessing data in scientific research and is frequently used to evaluate the risk of bias. Studies are categorized as high quality when they receive a PEDro score of 6 to 10, moderate quality when they receive a score of 4 to 5, and low quality when they receive a score of 0 to 3.

#### *Statistical evaluation*

Using RevMan 5.3, a meta-analysis of the extracted data was carried out. Odds ratios (ORs) with 95% confidence intervals (CIs) were used to express the statistical effect sizes for counts, and mean differences (MDs) with 95% confidence intervals (CIs) were used to express the statistical effect sizes for continuous data. When I<sup>2</sup> 50% suggested homogeneity, a fixed-effects model was utilized for the meta-analysis; a random-effects model was used when heterogeneity was present. Sensitivity analyses were performed using different effect models to evaluate the stability of the pooled results. Filter plots were generated to determine whether publication bias was present if there were ten or more primary studies.  $P < 0.05$  was considered to indicate statistical significance.

**Table S1** Detailed information on single nucleotide polymorphisms (SNPs) related to leakage factors and outcome factors.

	GWAS ID	Trait	Consortium	Sample Size	Number of SNPs
Type 2 diabetes	ebi-a-GCST006867	Type 2 diabetes	NA	655,666	5,030,727
Age	ebi-a-GCST90000050	Age at first birth	NA	542,901	9,702,772
Serum phosphorus	bbj-a-45	Phosphorus	NA	42,793	6,108,953
hemodialysis	finn-b-N14_DIALYSIS	Dialysis	NA	—	16,380,451

*Mendelian randomization analysis*

*Basic concept of MR analysis*

Regarding reverse causation and confounding, MR analysis is less vulnerable to bias than traditional observational methods because genetic variants are randomly distributed during gamete formation and are not correlated with environmental factors. Single-nucleotide polymorphisms (SNPs) linked to hemodialysis patient outcomes and death were identified in this study using MR analysis. Once the SNPs were identified, they were combined to evaluate the association between the risk of hemodialysis and significant factors linked to mortality during treatment. To ensure valid causal estimation, the following requirements must be met for each SNP to be used as an instrumental variable in MR analysis: (1) the genetic variation must be associated with significant hemodialysis mortality factors; (2) it cannot be affected by confounding factors; and (3) it must only affect the risk of hemodialysis through significant factors related to hemodialysis death.

*Data sources*

We used publicly available summary statistics from large-scale GWAS datasets in our two-sample MR analysis. As shown in *Table S1*, summary statistics for trauma infection and essential nutrients were retrieved from a GWAS database (<http://gwas.mrcieu.ac.uk/website>). The selected SNPs must strongly correlate with type 2 diabetes (T2D) incidence, dialysis status, age, zinc concentration, and serum phosphorus concentration for use in MR. We defined  $F > 10$  ( $F = N \cdot K - 1 / K \times R^2 / 1 - R^2$ ) as indicating no weak instrumental bias to guarantee a strong correlation between the selected SNPs and outcomes and prevent the bias of weak instrumental variables.  $R^2$  (the percentage of variance in the exposure database explained by SNPs) was calculated by the formula  $R^2 = 2 \times (1 - \text{MAF}) \times \text{MAF} \times (\beta / \text{SD})$ ;  $N$  and  $K$  are the sample sizes in the exposure database. The formula for calculation includes the secondary allele frequency (MAF), the allele effect value ( $\beta$ ), and the standard value (SD).

*MR analysis*

This work employs the inverse-variance weighting (IVW) method as its main methodology. IVW is well known for its resilience in identifying causal relationships. However, it presupposes that exposure affects the outcome and requires significant genetic variation. Four additional techniques are used to improve the accuracy of MR analysis: weighted mode, simple mode, weighted median estimator (WME), and MR Egger regression. High reliability was indicated by consistent results from all five of these MR analysis techniques. A value close to 0 indicates that horizontal pleiotropy is absent. This is the meaning of the intercept term in MR Egger regression. Significant P values indicate heterogeneity. The Cochran Q test was used to measure heterogeneity. A one-method exclusion analysis is carried out to guarantee the effects' general reliability. The study employs a significance level ( $\alpha$ ) of 0.05 for the results, which are displayed as odds ratios (ORs) and 95% confidence intervals (CIs). The R (v4.1) functions 'TwoSampleMR' and 'MRPRESSO' were used in all analyses.

**Results**

*Basic data from the meta-analysis*

Sixteen literary works were ultimately selected for analysis. There were 3,87025 patients in the total sample, and 30 important risk factors were identified. *Table S2* displays the specifics of the included studies.

*Meta-study results*

*Results of the random-effects model analysis*

Significant heterogeneity was observed ( $P < 0.001$ ,  $I^2 = 99.5\%$ ) in the death outcomes that were reported in all 16 hemodialysis studies. As shown in *Figure S1*, Galbraith's star chart indicated that certain studies were outside the confidence interval and that the slope of the scatter plot was significant. The Baujat plot continued to show heterogeneity even after removing the heterogeneous portion, as shown in *Figure S2*. Thus, for the meta-analysis, the




**Table S2** Literature details included.

Number	First author	Article type	Sample size	Reported outcomes	Country	Publication time	Quality score	Risk factors
1	Klinger Mr (9)	Review	61	All-cause mortality and cardiac death	Canada, USA	2019	7	1, 6, 23
2	Vicentini CAA (10)	Follow up research	592	All-cause mortality and cardiac death	Brazil	2023	8	1, 3, 7, 8, 10, 14, 21
3	Hiyamuta H (11)	Follow up research	3505	All-cause mortality and cardiac death	Japan	2020	6	1, 2, 4, 6, 9, 10, 11, 13, 15, 16, 19, 20, 23, 24, 25, 26, 28, 29, 30
4	Nakaya R (12)	Follow up research	516	All-cause mortality and cardiac death	Japan	2022	7	9, 17
5	Abe M (13)	Follow up research	203008	All-cause mortality and cardiac death	Japan	2021	7	2, 13, 19, 21, 23, 30
6	Gil Giraldo Y (14)	Prospective observational study	100	All-cause mortality and cardiac death	Spain	2020	8	1, 5, 9, 10, 12, 13, 15, 16, 22, 23, 30, 32
7	Yotsueda R (15)	Q-Cohort Study	3436	All-cause mortality and cardiac death	Japan	2017	8	1, 9, 26, 16, 30
8	Almeida FA (16)	Prospective observational study	334	All-cause mortality and cardiac death	Brazil	2010	6	1, 8, 15, 16, 27
9	Xiang F (17)	Follow up research	355	All-cause mortality and cardiac death	China	2017	9	1, 2, 6, 9, 10, 11, 15, 16, 23, 24, 30, 31
10	Jung YSg (18)	Follow up research	120	All-cause mortality and cardiac death	Korea	2014	7	1, 10, 16, 19, 30
11	Xiang F (19)	Follow up research	162360	All-cause mortality and cardiac death	Japan	2020	9	1, 9, 10, 13, 18, 30
12	Hall RK (20)	Follow up research	3500	All-cause mortality and cardiac death	USA	2018	7	1, 5, 11, 15, 19, 30
13	Abbott KC (21)	Follow up research	6939	All-cause mortality and cardiac death	USA	2018	7	1, 2, 9, 10
14	Fleischmann E (22)	Follow up research	1346	All-cause mortality and cardiac death	USA	1999	6	1, 2, 8, 10, 23, 30
15	Wu HC (23)	Retrospective study	176	All-cause mortality and cardiac death	China	2017	8	2, 10, 15, 16, 19, 23, 25, 30
16	Amaral S (24)	Retrospective study	677	All-cause mortality and cardiac death	USA	2006	6	1, 23, 30


Annotate: 1. Age; 2. BMI; 3. BSI-free days; 4. Cardiothoracic ratio; 5. Charlson index; 6. Cholesterol; 7. Comorbidities; 8. Creatinine; 9. CVD; 10. Diabetic; 11. Dialysis session length; 12. Dyslipidemia; 13. Hemodialysis vintage; 14. ESI-free days; 15. Hemoglobin; 16. Hypertension; 17. Infection; 18. Kidney disease; 19. Kt/V; 20. Non-use of VDRAs; 21. nPCR; 22. Peripheral vascular disease; 23. Serum albumin; 24. Serum corrected calcium; 25. Serum CRP; 26. Serum ferritin; 27. Serum Glucose; 28. Serum intact PTH; 29. Serum phosphorus; 30. Sex; 31. Smoke; 32. Stroke.

random-effects model was applied. Several significant variables, including BMI, age, sex, diabetes status, CVD incidence, haemoglobin status, hypertension status, Kt/V, hemodialysis vintage, serum CRP con-

centration, number of dialysis sessions, and CCI, were supported by multiple studies according to the results of the random-effects model meta-analysis ( $I^2=0.913$ ,  $P=0.181$ ), as shown in *Figure S3*.



**Figure S1** Galbraith plot of a meta-analysis with varying results.



**Figure S2** Baujat plot after partially removing heterogeneity.




Figure S3 The Forest Map of Meta-Analysis Results.

*Analytical results of the hierarchical random-effects model*

Stratified analysis was used to analyze the meta-analysis results further because it can significantly reduce heterogeneity. The heterogeneity did not differ substantially ( $P=0.1078$ ,  $I^2=91.06\%$ ), suggest-

ing that the heterogeneity increased with the combination of various factors. The results of the meta-analysis revealed several variables that were found to be significant by multiple studies. The dialysis session length, serum CRP concentration, CCI, T2D status, serum phosphorus concentration, and serum albumin concentration were also recorded (*Table S4*).

**Table S4** Meta-analysis results of a stratified random effects model.

Variable	estimate	se	zval	pval	ci.lb	ci.ub
intrcpt	0.171	0.077	2.223	0.026	0.020	0.321
BMI	-0.263	0.132	-1.990	0.047	-0.523	-0.004
Cardiothoracic ratio	0.020	0.281	0.071	0.943	-0.531	0.571
Charlson index	-0.066	0.214	-0.307	0.759	-0.485	0.354
Cholesterol	-0.363	0.185	-1.968	0.049	-0.725	-0.001
Comorbidities	0.012	0.291	0.040	0.968	-0.559	0.582
Creatinine	-0.102	0.193	-0.527	0.598	-0.480	0.277
CVD	0.234	0.142	1.644	0.100	-0.045	0.512
Diabetic	0.185	0.139	1.337	0.181	-0.086	0.457
Dialysis session length	-0.118	0.176	-0.673	0.501	-0.462	0.226
Dyslipidemia	0.235	0.608	0.386	0.699	-0.956	1.426
Hemodialysis vintage	-0.205	0.154	-1.332	0.183	-0.506	0.097
Haemoglobin	-0.258	0.136	-1.893	0.058	-0.524	0.009
Hypertension	-0.107	0.149	-0.719	0.472	-0.398	0.184
Infection	-1.444	0.428	-3.372	0.001	-2.283	-0.604
Kidney disease	-0.002	0.259	-0.006	0.995	-0.510	0.507
Kt/V	-0.305	0.159	-1.926	0.054	-0.616	0.005
Non-use of VDRA	-0.031	0.309	-0.100	0.921	-0.637	0.576
nPCR	-0.570	0.275	-2.069	0.039	-1.109	-0.030
Peripheral vascular disease	-0.527	0.718	-0.735	0.463	-1.934	0.880
Serum albumin	-0.593	0.133	-4.454	0.000	-0.854	-0.332
Serum corrected calcium	-0.141	0.219	-0.644	0.519	-0.570	0.288
Serum CRP	-0.017	0.205	-0.081	0.935	-0.418	0.385
Serum ferritin	-0.171	0.273	-0.625	0.532	-0.706	0.365
Serum Glucose	1.183	0.442	2.677	0.007	0.317	2.049
Serum intact PTH	-0.171	0.273	-0.624	0.532	-0.706	0.365
Serum phosphorus	-0.031	0.280	-0.110	0.912	-0.579	0.517
Sex	-0.052	0.125	-0.414	0.679	-0.296	0.193
Smoke	-0.221	0.352	-0.628	0.530	-0.910	0.469
Stroke	0.523	0.740	0.706	0.480	-0.927	1.972



*Sensitivity analysis and deviation testing*

As seen in *Figure S5*, The horizontal pleiotropy test results ( $T=0.39$ ,  $df=116$ ,  $P=0.6953$ ) indicated no horizontal pleiotropy. the results of the sensitivity analysis ( $P=0.1186$ ,  $I^2=99.53\%$ ) demonstrated the general stability of the data.

*Mendelian randomization analysis*

According to the GWAS data, no SNPs with significant differences in meta-analysis scores, including session length, serum CRP concentration, or CCI, were detected. Thus, the analysis focused solely on the associations of T2D incidence, serum phosphorus concentration, and serum albumin concentration with hemodialysis.


*Selection Results of IVs*

Nineteen SNPs without linkage imbalance were identified from the exposure datasets for serum albumin, age, T2D status, and serum phosphorus (rs13234269, rs1758632, rs6494307, rs2058913, rs10752613, rs13420733, rs4443016, rs62261746, rs13319205, rs2530597, rs1464534, rs1590949, rs7958796, rs7359501, rs10445366, rs5763436, rs733323, rs2389858, and rs2001945). These SNPs were selected as instrumental variables to assess their relationships with hemodialysis. The F-

statistics for these SNPs ranged from 63.14 to 148.48 (Serum albumin), 19.39 to 261.55 (age), 26.13 to 92.40 (T2D), and 51.93 to 126.16 (Serum phosphorus).

*Age, serum albumin concentration, type 2 diabetes incidence, serum phosphorus concentration, and hemodialysis Mendelian randomization results*


The IVW results indicated a positive causal relationship between T2D and hemodialysis at the genetic level ( $OR=1.2572$ , 95%  $CI=1.0375-1.5235$ ;  $P=0.0195$ ). There was also a positive correlation between the serum phosphorus concentration and hemodialysis status at the genetic level ( $OR=2.0269$ , 95%  $CI=1.0614-3.8708$ ;  $P=0.0323$ ). However, age ( $OR=1.1112$ , 95%  $CI=0.8395-1.4707$ ;  $P=0.4612$ ) and serum albumin concentration ( $OR=1.2933$ , 95%  $CI=0.8931-1.8729$ ;  $P=0.1733$ ) did not show a positive causal relationship at the gene level with hemodialysis. The specific results are presented in *Table I*. The IVW results were validated through MR Egger, WME, weighted mode, and simple mode analyses. The scatter plot confirmed that the regression lines for age predicted by genetics, T2D status, serum phosphorus concentration, and serum albumin concentration were largely consistent with the risk of hemodialysis, indicating the reliability of the MR analysis results, as shown in *Figure 2*.



**Figure S5** Funnel plot of a meta-analysis on the impact of publication bias.

**Table 1** OR estimates for Inverse Variance Weighted (IVW), Mendelian Randomization (MR) Egger regression, Weighted Median Estimator (WME), Weighted Mode, Simple Mode, and 95% confidence interval (CI).


Exposure	Outcome	Number of SNPs	Method	SE	P	OR	95%CI	
Type 2 diabetes	hemodialysis	114	MR Egger	1.0682	0.7292	1.0843	0.6865	1.7127
		114	Weighted median	0.3999	0.5571	1.0836	0.8288	1.4169
		114	Inverse variance weighted	0.3301	0.0195	1.2572	1.0375	1.5235
		114	Simple mode	0.558	0.6202	1.1611	0.6441	2.0931
		114	Weighted mode	0.4849	0.7558	1.0512	0.7679	1.4392
Serum phosphorus	hemodialysis	8	MR Egger	1.0682	0.8919	1.1636	0.1434	9.4412
		8	Weighted median	0.3999	0.1096	1.8962	0.8659	4.1521
		8	Inverse variance weighted	0.3301	0.0323	2.0269	1.0614	3.8708
		8	Simple mode	0.558	0.0795	3.1396	1.0518	9.372
		8	Weighted mode	0.4849	0.3649	1.5996	0.6184	4.1373
Serum albumin	hemodialysis	224	MR Egger	0.3569	0.6586	1.1711	0.5818	2.3574
		224	Weighted median	0.3116	0.2808	1.3995	0.7598	2.5778
		224	Inverse variance weighted	0.1889	0.1733	1.2933	0.8931	1.8729
		224	Simple mode	0.6764	0.6690	1.3358	0.3548	5.0293
		224	Weighted mode	0.3453	0.5370	1.2381	0.6292	2.4361
Age	hemodialysis	55	MR Egger	0.5909	0.7059	1.2512	0.3930	3.9837
		55	Weighted median	0.1928	0.3825	1.1834	0.8110	1.7268
		55	Inverse variance weighted	0.1430	0.4612	1.1112	0.8395	1.4707
		55	Simple mode	0.5127	0.3833	0.6372	0.2333	1.7406
		55	Weighted mode	0.4279	0.3278	1.5257	0.6596	3.5292




**Figure 2** Shows scatter plots of the causal effect (A: Type 2 diabetes and hemodialysis; and B: Serum phosphorus and hemodialysis).

**Table II** Sensitivity analysis of various MRI studies.

Exposure	Outcome	Cochran Q		MR Egger		MR-PRESSO	
		MR Egger	IVW	intercept	P	Outlier	P
Type 2 diabetes	hemodialysis	P=0.9739	P=0.9803	0.0418	0.6045	0.017	0.486
Serum phosphorus	hemodialysis	P=0.0032	P=0.0035	0.0117	0.4857	0.077	0.605
Age	hemodialysis	P=0.0895	P=0.1047	-0.0084	0.8366	0.040	0.836
Serum albumin	hemodialysis	P=0.1837	P=0.1950	0.0028	0.7432	0.009	0.743



**Figure 3** Residual forest plot of causal effect relationship (A: Type 2 diabetes and hemodialysis; and B: Serum phosphorus and hemodialysis).



**Figure 4** Funnel plot of causal effect relationship (A: Type 2 diabetes and hemodialysis; and B: Serum phosphorus and hemodialysis).

#### Horizontal pleiotropy analysis and heterogeneity test

According to the results of the MR Egger intercept analysis, no potential pleiotropy was found for age ( $P=0.8366$ ), serum albumin concentration ( $P=0.7432$ ), T2D status ( $P=0.6045$ ), or serum phosphorus concentration ( $P=0.4857$ ). This finding implies that other than exposure, instrumental variables had no discernible impact on the outcomes. Cochran's  $Q$  heterogeneity test indicated potential heterogeneity in the serum phosphorus concentration (IVW  $P=0.0035$ , MR Egger  $P=0.0032$ ). Age (IVW  $P=0.1047$ , MR Egger  $P=0.0895$ ) and serum albumin concentrations in patients with T2D (IVW  $P=0.9803$ , MR Egger  $P=0.9739$ ) did not significantly affect the outcome. Table II illustrates that no discernible heterogeneity was found. The leave-one-out method confirmed that the overall causality estimation was unaffected by any individual SNP. The outcome is displayed in Figure 3. A symmetrical funnel plot that illustrates the distribution of causal effects implies that no underlying factors influence the outcomes. The outcome is shown in Figure 4.

## Discussion

Thirty-two risk factors were linked to mortality in hemodialysis patients based on our analysis of sixteen studies. The significant factors we identified after performing a meta-analysis using both random- and

stratified-effects models were the serum CRP concentration, CCI, dialysis status, T2D status, serum phosphorus concentration, and heterogeneity. Reduced serum albumin concentrations are essential risk factors linked to hemodialysis patient deaths. A genetic causal relationship was found between the serum phosphorus concentration and the risk of hemodialysis according to the results of MR analysis, with T2D, age, the serum albumin concentration, and the serum phosphorus concentration as critical factors and hemodialysis as the result. Consequently, this study used MR and meta-analysis to demonstrate that T2D and serum phosphorus levels are significant risk factors for hemodialysis occurrence and positively correlate with death in hemodialysis patients.

Our study aimed to identify mortality risk factors in hemodialysis patients using a systematic review and meta-analysis and to investigate the causal relationships between serum phosphorus, albumin, and CRP and hemodialysis risk using Mendelian randomization analysis. Our results identified serum phosphorus, albumin, and CRP as mortality risk factors in hemodialysis patients, consistent with previous studies (25, 26). The Mendelian randomization analysis revealed a positive causal relationship between serum phosphorus and hemodialysis risk, suggesting that high serum phosphorus levels may increase the mortality risk in hemodialysis patients. Our findings are consistent with a recent study by Yan et al. (25), which found that genetically predicted reduced glomerular filtration rate was associated with higher odds of appendicular lean mass and grip

strength, suggesting a potential causal relationship between renal function and sarcopenia (25). Similarly, our study found that serum phosphorus, a marker of renal function, was positively associated with hemodialysis risk. Another study by Zhou et al. (26) found that increased serum iron, ferritin, and transferrin saturation were associated with elevated immunoglobulin A nephropathy risk, suggesting a potential causal effect of systemic iron status on kidney disease (26). Our study did not investigate the relationship between iron status and hemodialysis risk. A genome-wide association study by Siew et al. (27) identified two novel loci associated with acute kidney injury, including a locus near the FTO gene that was attenuated after adjustment for BMI and diabetes (27). Our study did not investigate the relationship between genetic variants and hemodialysis risk. A Mendelian randomization study by Hou et al. (28) found that N-acetylserine and glycine to alanine ratio were associated with lower and higher risk of chronic kidney disease, respectively (28). Our study did not investigate the relationship between metabolites and hemodialysis risk.

According to the consensus statement issued by the Swiss Society of Diabetes and Nephrology, the main cause of end-stage renal disease in people with T2D is their heightened risk of developing diabetic nephropathy. Improving early screening for diabetic nephropathy and increasing clinicians' knowledge of the condition is crucial. Early clinical intervention can lessen patients' financial burden while also improving clinical outcomes (29). Diabetes increases the risk of frailty in end-stage renal disease patients undergoing hemodialysis treatment, according to the findings of a systematic review and meta-analysis. Additionally, patients with frailty had a greater risk of death than patients without frailty (OR=2.02, 95% CI=1.65–2.48) (30). In a study examining risk factors associated with death in patients undergoing hemodialysis treatment or peritoneal dialysis for end-stage renal disease and T2D, high cholesterol levels at the start of peritoneal dialysis treatment were found to be independent risk factors for death. A lower BMI and higher HbA1c level were risk factors linked to mortality during hemodialysis treatment. Nursing care for patients with end-stage renal disease or T2D who are undergoing hemodialysis treatment should be customized based on the patient's nutritional status. To reduce and prevent the risk of death and disease progression in these patients, targeted nursing programs should be created. Simultaneously, tracking variations in HbA1c levels as the nursing process progresses is crucial. Patients should be closely monitored, and the nursing and clinical treatment plan should be modified if there is a persistent or abrupt increase in HbA1c (31).

Dietary sources or endogenous production are the sources of serum phosphorus. Fibroblast growth factor-23 (FGF-23) and parathyroid hormone (PTH) are both stimulated by phosphorus. Both phosphaturic hormones, FGF-23 and PTH, promote phosphate

absorption from the blood via NaPi-2a on the apical membrane of renal tubules. This absorption mode promotes phosphorus excretion and limits phosphate reabsorption in the urine. Hyperphosphatemia and elevated FGF-23 expression are frequently observed in patients with chronic kidney disease. In cardiomyocytes, elevated expression levels of FGF-23 stimulate the transcription of genes linked to pathological hypertrophy, resulting in left ventricular hypertrophy. Hyperphosphatemia and Klotho deficiency are concomitant with reduced endothelial cell function, increased arterial wall calcification, and valvular disease. Hyperphosphatemia and elevated FGF-23 expression are the main risk factors for cardiovascular disease development in individuals with chronic kidney disease (32, 33). The main cause of death for patients with chronic kidney disease undergoing hemodialysis treatment is concurrent cardiovascular disease. Intensive hemodialysis management has been shown to lower patient mortality by lowering the risk of adverse cardiac events (34).

## Conclusion

According to our research, T2D and serum phosphorus are significant independent risk factors for mortality in hemodialysis patients as well as hemodialysis patients with end-stage renal disease. Patients suffering from hyperphosphatemia and diabetic nephropathy require close observation and monitoring throughout their clinical and nursing care.

## Author contributions

All authors have made substantial contributions to the conception and design of the study. Xiaofen Ma has been involved in data analysis, data interpretation, drafting the manuscript, and revising it critically. Huan Ye and Xiaofen Ma have designed the study and critically revised the manuscript. Huan Ye gave the final approval for the version to be published.

**Acknowledgements.** We thank the researchers for sharing their data on the GWAS data.

## Ethics statement

Each cohort in this study received the approval of the respective institutional research ethics board to enrol patients, and all participants provided written informed consent. All information used for this study is publicly available as deidentified GWAS summary statistics.

## Conflict of interest statement

All the authors declare that they have no conflict of interest in this work.



## References

1. Tao S, Li X, Liu Z, et al. Investigation on maintenance hemodialysis patients with mineral and bone disorder in Anhui province. China. *Int Urol Nephrol* 2023; 55(2): 389–98. Doi: 10.1007/s11255-022-03328-9.
2. Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. *Kidney International Supplements*. 2022 Apr 1; 12(1): 7–11.
3. Bossola M, Di Napoli A, Angelici L, Bargagli AM, Cascini S, Kirchmayer U, Agabiti N, Davoli M, Marino C. Trend and determinants of mortality in incident hemodialysis patients of the Lazio region. *BMC Nephrology* 2023 Apr 26; 24(1): 111.
4. Bello AK, Okpechi IG, Osman MA, Cho Y, Htay H, Jha V, Wainstein M, Johnson DW. Epidemiology of haemodialysis outcomes. *Nature Reviews Nephrology* 2022 Jun; 18(6): 378–95.
5. de Arriba G, Avila GG, Guinea MT, Alia IM, Herruzo JA, Ruiz BR, Tejeiro RD, Rubio ME, Poyatos CV, Roldán CG. Mortality of hemodialysis patients is associated with their clinical situation at the start of treatment. *Nefrología (English Edition)*. 2021 Jul 1; 41(4): 461–6.
6. Yang, M, Yang, Y, Xu, Y, Wu, Y, Lin, J, Mai, J, Fang, K, Ma, X, Zou, C and Lin, Q, 2023. Development and Validation of Prediction Models for All-Cause Mortality and Cardiovascular Mortality in Patients on Hemodialysis: A Retrospective Cohort Study in China. *Clinical Interventions in Aging*, pp. 1175–90.
7. Chandrashekar A, Ramakrishnan S, Rangarajan D. Survival analysis of patients on maintenance hemodialysis. *Indian Journal of Nephrology*. 2014 Jul 1; 24(4): 206–13.
8. Mailloux LU, Bellucci AG, Wilkes BM, Napolitano B, Mossey RT, Lesser M, Bluestone PA. Mortality in dialysis patients: analysis of the causes of death. *American journal of kidney diseases* 1991 Sep 1; 18(3): 326–35.
9. Klinger M, Madziarska K. Mortality predictor pattern in hemodialysis and peritoneal dialysis in diabetic patients. *Adv Clin Exp Med* 2019; 28(1): 133–5. Doi: 10.17219/acem/76751.
10. Vicentini CAA, Ponce D. Comparative analysis of patients' survival on hemodialysis vs. peritoneal dialysis and identification of factors associated with death. *J Bras Nefrol* 2023; 45(1): 8–16. Doi: 10.1590/2175-8239-JBN-2021-0242en.
11. Hiya-muta H, Tanaka S, Taniguchi M, et al. The Incidence and Associated Factors of Sudden Death in Patients on Hemodialysis: 10-Year Outcome of the Q-Cohort Study. *J Atheroscler Thromb* 2020; 27(4): 306–18. Doi: 10.5551/jat.49833.
12. Nakaya R, Shoji T, Nagata Y, et al. Associations of Serum Insulin-Like Growth Factor 1 with New Cardiovascular Events and Subsequent Death in Hemodialysis Patients: The DREAM Cohort. *J Atheroscler Thromb* 2022; 29(8): 1153–65. Doi: 10.5551/jat.62992.
13. Abe M, Masakane I, Wada A, et al. High-performance dialyzers and mortality in maintenance hemodialysis patients. *Sci Rep* 2021; 11(1): 12272. Doi: 10.1038/s41598-021-91751-w.
14. Gil Giraldo Y, Muñoz Ramos P, Ruano P, et al. Vascular access-related mortality in hemodialysis patients during and after hospitalization. *Ther Apher Dial* 2020; 24(6): 688–94. Doi: 10.1111/1744-9987.13479.
15. Yotsueda R, Taniguchi M, Tanaka S, et al. Cardiothoracic Ratio and All-Cause Mortality and Cardiovascular Disease Events in Hemodialysis Patients: The Q-Cohort Study. *Am J Kidney Dis* 2017; 70(1): 84–92. Doi: 10.1053/j.ajkd.2016.11.026.
16. Almeida FA, Machado FC, Moura JA Jr, et al. Global and cardiovascular mortality and risk factors in patients under hemodialysis treatment. *Arq Bras Cardiol* 2010; 94(2): 187–92, 201–6; 190–5. Doi: 10.1590/s0066-782x2010005000003.
17. Xiang F, Chen R, Cao X, et al. Monocyte/lymphocyte ratio as a better predictor of cardiovascular and all-cause mortality in hemodialysis patients: A prospective cohort study. *Hemodial Int* 2018; 22(1): 82–92. Doi: 10.1111/hdi.12549.
18. Jung YS, You G, Shin HS, et al. Relationship between Geriatric Nutritional Risk Index and total lymphocyte count and mortality of hemodialysis patients. *Hemodial Int* 2014; 18(1): 104–12. Doi: 10.1111/hdi.12077.
19. Xiang F, Chen R, Cao X, et al. Monocyte/lymphocyte ratio as a better predictor of cardiovascular and all-cause mortality in hemodialysis patients: A prospective cohort study. *Hemodial Int* 2018; 22(1): 82–92. Doi: 10.1111/hdi.12549.
20. Hall RK, Luciano A, Pieper C, et al. Association of Kidney Disease Quality of Life (KDQOL-36) with mortality and hospitalization in older adults receiving hemodialysis. *BMC Nephrol* 2018; 19(1): 11. Doi: 10.1186/s12882-017-0801-5.
21. Abbott KC, Fwu CW, Eggers PW, et al. Opioid Prescription, Morbidity, and Mortality in US Transplant Recipients Transplantation 2018; 102(6): 994–1004. Doi: 10.1097/TP.0000000000002057.
22. Fleischmann E, Teal N, Dudley J, et al. Influence of excess weight on mortality and hospital stay in 1346 hemodialysis patients. *Kidney Int* 1999; 55(4): 1560–7. Doi: 10.1046/j.1523-1755.1999.00389.x.
23. Wu HC, Tseng SF, Wang WJ, et al. Association between obesity with low muscle mass and dialysis mortality. *Intern Med J* 201; 47(11): 1282–91. Doi: 10.1111/imj.13553.
24. Amaral S, Hwang W, Fivush B, et al. Association of mortality and hospitalization with achievement of adult hemoglobin targets in adolescents maintained on hemodialysis. *J Am Soc Nephrol* 2006; 17(10): 2878–85. Doi: 10.1681/ASN.2005111215.
25. Yan P, Ke B, Fang X. Identification of molecular mediators of renal sarcopenia risk: a mendelian randomization analysis. *The Journal of Nutrition, Health and Aging* 2024 Jan 1; 28(1): 100019.
26. Zhou J, Shi W, Wu D, Wang S, Wang X, Min J, Wang F. Mendelian Randomization Analysis of Systemic Iron Status and Risk of Different Types of Kidney Disease. *Nutrients* 2024 Jun 21; 16(13): 1978.
27. Siew ED, Hellwege JN, Hung AM, Birkelo BC, Vincz AJ, Parr SK, Denton J, Greevy RA, Robinson-Cohen C, Liu H,

- Susztak K. Genome-wide association study of hospitalized patients and acute kidney injury. *Kidney International* 2024 Aug 1; 106(2): 291–301.
28. Hou Y, Xiao Z, Zhu Y, Li Y, Liu Q, Wang Z. Blood metabolites and chronic kidney disease: a Mendelian randomization study. *BMC Medical Genomics* 2024 May 28; 17(1): 147.
29. Zanchi A, Jehle AW, Lamine F, et al. Diabetic kidney disease in type 2 diabetes: a consensus statement from the Swiss Societies of Diabetes and Nephrology. *Swiss Med Wkly* 2023; 153: 40004. Doi: 10.57187/smw.2023.40004.
30. Lee HJ, Son YJ. Prevalence and Associated Factors of Frailty and Mortality in Patients with End-Stage Renal Disease Undergoing Hemodialysis: A Systematic Review and Meta-Analysis. *Int J Environ Res Public Health* 2021; 18(7):3471. Doi: 10.3390/ijerph18073471.
31. Liu H, He Z, Hu X, et al. Propensity-matched comparison of mortality between peritoneal dialysis and hemodialysis in patients with type 2 diabetes. *Int Urol Nephrol* 2022; 54(6): 1373–81. Doi: 10.1007/s11255-021-03026-y.
32. Wang M, Zhang J, Kalantar-Zadeh K, et al. Focusing on Phosphorus Loads: From Healthy People to Chronic Kidney Disease. *Nutrients* 2023; 15(5): 1236. Doi: 10.3390/nu15051236.
33. Picard K, Mager DR, Richard C. The Impact of Protein Type on Phosphorus Intake, Serum Phosphate Concentrations, and Nutrition Status in Adults with Chronic Kidney Disease: A Critical Review. *Adv Nutr.* 2021; 12(6): 2099–111. Doi: 10.1093/advances/nmab062.
34. McCullough PA, Chan CT, et al. Intensive Hemodialysis, Left Ventricular Hypertrophy, and Cardiovascular Disease. *Am J Kidney Dis* 2016; 68(5S1): S5–S14. Doi: 10.1053/j.ajkd.2016.05.025.

*Received: June 15, 2024*

*Accepted: October 07, 2024*